Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will take place virtually from April 10-15 and May 17-21, 2021.
| CAMBRIDGE, Mass., March 19, 2021 /PRNewswire/ -- Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will take place virtually from April 10-15 and May 17-21, 2021. The posters will describe insights into exoneural biology discovered via Cygnal’s Exoneural Medicine Platform™ (EMP). Poster Title: Neural communication to peripheral tumors regulates cancer cell activity Poster Title: Novel mechanisms of Neuropilin-1 inhibition result in improved tumor growth inhibition in vivo Both posters will be offered virtually, and Cygnal’s presenters will be available to answer questions via the AACR’s online system during and after the event. The posters will be available for viewing by registered attendees from April 10 until June 21, 2021. About Cygnal Therapeutics
SOURCE Cygnal Therapeutics |
View original content:
